Immunomic Therapeutics inks license deal with Ichor

By The Science Advisory Board staff writers

June 16, 2020 -- Immunomic Therapeutics (ITI) has signed a licensing agreement with Ichor Medical Systems to support the development of its ITI-1001 investigational plasmid DNA vaccine therapy.

ITI will use Ichor's TriGrid electroporation delivery technology to increase the cellular uptake of ITI-1001 when administered to patients with newly diagnosed glioblastoma multiforme (GBM). ITI-1001 is designed to target the pp65, ie-1, and gB viral antigens of cytomegalovirus (CMV), which are expressed in GBM, but not in normal brain cells, according to the company.

The first in-human phase I study for ITI-1001 is expected to begin in 2021.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.